Bayer has started a program to prevent dog and horse diarrhea from being passed on to humans.
The German drugmaker has developed a deworming tool that detects the presence of bacteria in the stool and can then activate the immune system to remove it.
It has also developed a vaccine that could be administered to the dog and the horse for up to 10 years.
“The tool is the result of our collaboration with scientists from the German Institute of Veterinary Medicine, and its aim is to protect people from the most common forms of canine diarrhea,” said Bayer CEO Jörg-Ulrich Brand, who is also the CEO of the pharmaceutical company’s dog division.
The tool works by identifying the bacteria in stool samples and detecting a chemical signature of the bacteria, which is used to detect whether it is a canine or human pathogen.
If it detects the human pathogenic bacteria, it then activates the immune response to rid the stool of the pathogen, preventing it from spreading.
“If the stool has been contaminated by human feces, then the detection of the human bacteria is also detected,” said Brand.
“This tool is highly sensitive to human and canine feces and can detect only those bacteria that have been identified in the human stool.
So it can detect the presence only of the pathogens that are present in the contaminated stool.”
Bayer has now released the dewormed and deworm-infected dogs, horses and other pets on the market, with the aim of encouraging consumers to use the product and to share their experiences with their pets.
Bayer will distribute the deworms and the vaccine to dog owners through the company’s website, and it will also send out coupons for its deworm product, the company said.
Beset by the canine diarrhea epidemic, Bayer is currently seeking new ways to reduce the burden of canine infections.
The company plans to create a new canine diarrhea vaccine, and a new treatment for canine diarrhea called LAMACO (Laser Affective Management for Co-infection with Infectious Disease).
It will also expand its collaboration with the American Veterinary Medical Association (AVMA), which is studying a potential canine vaccine.
In addition, Bayer will also develop an anti-bacterial agent, called KAIC, which it plans to test in dogs.
Bissel said the company has received over 400 applications for the deworm tool.
“We have already tested a lot of them and are still waiting for an overwhelming number of valid ones,” he said.
“Some people have been waiting for over a year, and they still haven’t received the tool.”
The company said it hopes to have a complete product in 2020.